M
Marie-Anne Raquin
Researcher at Institut Gustave Roussy
Publications - 37
Citations - 2815
Marie-Anne Raquin is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Cancer & Procarbazine. The author has an hindex of 22, co-authored 37 publications receiving 2666 citations.
Papers
More filters
Journal ArticleDOI
Long-term intellectual outcome in children with posterior fossa tumors according to radiation doses and volumes.
Jacques Grill,Virginie Kieffer Renaux,C. Bulteau,Delphine Viguier,Christine Levy-Piebois,Christian Sainte-Rose,Georges Dellatolas,Marie-Anne Raquin,Isabelle Jambaqué,Chantal Kalifa +9 more
TL;DR: This preliminary study further supports the rationale for de-escalation of CSI doses and volumes in standard-risk PF tumors and shows a significant correlation between the full-scale IQ score and the CSI dose.
Journal ArticleDOI
Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children
Jacques Grill,Christian Sainte-Rose,Anne Jouvet,Jean-Claude Gentet,Odile Lejars,Didier Frappaz,François Doz,Xavier Rialland,Fabienne Pichon,Anne-Isabelle Bertozzi,Pascal Chastagner,Dominique Couanet,Jean-Louis Habrand,Marie-Anne Raquin,Marie-Cécile Le Deley,Chantal Kalifa +15 more
TL;DR: Conventional chemotherapy alone can be used to cure children with non-metastatic medulloblastoma who have gross total resection confirmed by early radiological assessment, but is not sufficient for treatment of those with metastatic or incompletely resected medullOBlastoma.
Journal ArticleDOI
Postoperative Chemotherapy Without Irradiation for Ependymoma in Children Under 5 Years of Age: A Multicenter Trial of the French Society of Pediatric Oncology
Jacques Grill,Marie-Cécile Le Deley,Danièle Gambarelli,Marie-Anne Raquin,Dominique Couanet,Alain Pierre-Kahn,Jean-Louis Habrand,François Doz,Didier Frappaz,Jean-Claude Gentet,Christine Edan,Pascal Chastagner,Chantal Kalifa +12 more
TL;DR: A significant proportion of children with ependymoma can avoid radiotherapy with prolonged adjuvant chemotherapy, and deferring irradiation at the time of relapse did not compromise overall survival of the entire patient population.
Journal ArticleDOI
Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics.
Sarah Fattet,Sarah Fattet,Sarah Fattet,Christine Haberler,Christine Haberler,Christine Haberler,Patricia Legoix,Pascale Varlet,Arielle Lellouch-Tubiana,Arielle Lellouch-Tubiana,Séverine Lair,Séverine Lair,Séverine Lair,Elodie Manié,Elodie Manié,Marie-Anne Raquin,D. Bours,Sabrina Carpentier,Sabrina Carpentier,Sabrina Carpentier,Emmanuel Barillot,Emmanuel Barillot,Emmanuel Barillot,Jacques Grill,François Doz,François Doz,Stéphanie Puget,Isabelle Janoueix-Lerosey,Isabelle Janoueix-Lerosey,Olivier Delattre,Olivier Delattre +30 more
TL;DR: Data confirm and extend previous observations that CTNNB1‐mutated tumours represent a distinct molecular subgroup of medulloblastomas with favourable outcome, indicating that therapy de‐escalation should be considered.
Journal ArticleDOI
Risk of Secondary Leukemia After a Solid Tumor in Childhood According to the Dose of Epipodophyllotoxins and Anthracyclines: A Case-Control Study by the Société Française d’Oncologie Pédiatrique
Marie-Cécile Le Deley,Thierry Leblanc,A Shamsaldin,Marie-Anne Raquin,Brigitte Lacour,Danièle Sommelet,Agnès Chompret,Jean-Michel Cayuela,Chantal Bayle,Alain Bernheim,Florent de Vathaire,Gilles Vassal,Catherine Hill +12 more
TL;DR: Both epipodophyllotoxins and anthracyclines increase the risk of secondary leukemia, and the current challenge is to minimize the mutagenic effects of these drugs by diminishing cumulative doses without losing the therapeutic benefits.